Payment overview · 2025
General Payments
$867.82
23 reported records · 9 companies
Healthcare provider profile · identity verified
Douglas B Grisier, DO
Allopathic & Osteopathic Physicians|Family Medicine · ERIE, PA · NPI 1043276934
Verified facts
What the public records show
CMS Open Payments records show Douglas B Grisier, DO received $867.82 in general payments during 2025 across 23 reported records.
Amgen Inc. accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $316.22 | 36.4% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $190.73 | 22.0% | 8 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $116.97 | 13.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $101.47 | 11.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.71 | 7.0% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $26.67 | 3.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $23.62 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.81 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.62 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $867.82 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $191.32 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $157.46 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $149.14 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $116.97 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $101.47 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.71 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.59 | 5 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
91 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 631 | 144 |
| Atorvastatin Calcium | Atorvastatin Calcium | 540 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 326 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 296 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 287 | 62 |
| Lisinopril | Lisinopril | 225 | 44 |
| Levetiracetam | Levetiracetam | 210 | 32 |
| Gabapentin | Gabapentin | 206 | 54 |
| Metformin Hcl | Metformin Hcl | 188 | 35 |
| Omeprazole | Omeprazole | 186 | 30 |
| Furosemide | Furosemide | 168 | 42 |
| Potassium Chloride | Potassium Chloride | 160 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 45 |
| Oxycodone Hcl | Oxycodone Hcl | 135 | 48 |
| Eliquis | Apixaban | 133 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 44 |
| Lorazepam | Lorazepam | 126 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 27 |
| Simvastatin | Simvastatin | 124 | 21 |
| Losartan Potassium | Losartan Potassium | 123 | 27 |
| Famotidine | Famotidine | 118 | 24 |
| Baclofen | Baclofen | 117 | 17 |
| Trazodone Hcl | Trazodone Hcl | 117 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 113 | 33 |
| Meloxicam | Meloxicam | 113 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 20 |
| Lamotrigine | Lamotrigine | 101 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 12 |
| Trulicity | Dulaglutide | 91 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 18 |
| Ibuprofen | Ibuprofen | 76 | 20 |
| Nystatin | Nystatin | 76 | 17 |
| Tramadol Hcl | Tramadol Hcl | 73 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | suppressed |
| Bumetanide | Bumetanide | 65 | 22 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 63 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 63 | 22 |
| Topiramate | Topiramate | 63 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 61 | 17 |
| Mirtazapine | Mirtazapine | 58 | 11 |
| Alendronate Sodium | Alendronate Sodium | 55 | suppressed |
| Ketoconazole | Ketoconazole | 55 | 13 |
| Carvedilol | Carvedilol | 54 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 15 |
| Lactulose | Lactulose | 49 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 12 |
| Amantadine | Amantadine Hcl | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Finasteride | Finasteride | 45 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Risperidone | Risperidone | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 37 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | 11 |
| Loperamide | Loperamide Hcl | 35 | 11 |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | 13 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Methocarbamol | Methocarbamol | 31 | 15 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Zonisamide | Zonisamide | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | 13 |
| Diazepam | Diazepam | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Xtampza Er | Oxycodone Myristate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $867.82 · 23 records | Amgen Inc. | BREZTRI, Cologuard Collection Kit, MOUNJARO, OTEZLA, REPATHA, REZDIFFRA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VIVITROL, WATCHMAN Access System, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error